Global and China Benign Prostatic Hyperplasia Medication Industry Professional Market Report 2017

August 2017 | 133 pages | ID: GF7FC1C18E0EN
QYResearch

Abstracts

This report splits Benign Prostatic Hyperplasia Medication market by 5α-reductase inhibitors, by α-receptor antagonist, by Plant Preparations, by Others, which shares the history data information from 2012 to 2016 and forecast from 2017 to 2022.
This report mainly introduces volume and value market share by players, by regions, by product type, by consumers and also their price change details.
This report focus Global and China market, coving details as following:
Key Players

• MSD PHARMA (SINGAPORE) PTE.LTD.
• Merck Sharp & Dohme Limited
• GlaxoSmithKline (Ireland) Limited
• Pfizer Pharma GmbH
• Sanofi-Aventis France
• ABBOTT LABORATORIES
• Astellas Pharma Inc.
• AMNEAL PHARMS
• ANCHEN PHARMS
• APOTEX INC
• ASCENT PHARMS INC
• AUROBINDO PHARMA
• BARR
• BIONPHARMA INC
• BOEHRINGER INGELHEIM
• BRECKENRIDGE PHARM
• CIPLA LTD
• AUROBINDO PHARMA LIMITED IN 500 038 Hyderabad
• Bioindustria L.I.M. S.p.A. IT 15067 Novi Ligure
• CADILA HEALTHCARE LIMITED IN 391 440 Dabhasa Village
• CIPLA LIMITED IN 400 013 Mumbai
• CRYSTAL PHARMA S.A.U. ES 47151 Boecillo
• DR. REDDY'S LABORATORIES LIMITED IN 500 034 Hyderabad
• EXCELLA GMBH & CO. KG DE 90537 Feucht
• Farmak A.S. CZ 779 00 Olomouc
• HETERO LABS LIMITED IN 500 018 Hyderabad
• Hubei Gedian Humanwell Pharmaceutical Co., Ltd. CN 436 070 E-Zhou
• MSN LABORATORIES PRIVATE LIMITED IN 502 329 Rudraram Village

Key Regions

• Asia Pacific
• China
• First-tier Cities
• Second-tier Cities
• Third-tier Cities
• Others
• Japan
• Korea
• India
• Others
• Europe
• France
• Germany
• United Kingdom
• Italy
• Russia
• Others
• North America
• United States
• Canada
• Latin America
• Brazil
• Mexico
• Others
• Southeast Asia
• Singapore
• Malaysia
• Vietnam
• Myanmar
• Thailand
• Indonesia
• Philippines
• Others
• Middle East & Africa
• Saudi Arabia
• Iran
• UAE
• Turkey
• Israel
• Egypt
• South Africa
• Others

Key Product Type
Benign Prostatic Hyperplasia Medication Market, by 5α-reductase inhibitors

• Finasteride
• Dutasteride
• Epristeride

Benign Prostatic Hyperplasia Medication Market, by α-receptor antagonist

• Pheoxbenzamine
• Doxazosin
• Alfuzosin
• Terazosin
• Prarizonaosin
• Tamsulosin
• Naftopidil

Benign Prostatic Hyperplasia Medication Market, by Plant Preparations

• Prostat
• Cernilton
• Compound blue palm fruit

Benign Prostatic Hyperplasia Medication Market, by Others

• Flavoxate
• glu-ala-glycine

Key Consumers (End User)

• urinary surgery
• Pharmacy
• Hospital
• Clinic

Contents

Global and China Benign Prostatic Hyperplasia Medication Industry Professional Market Report 2017

CHAPTER ONE GLOBAL AND CHINA BENIGN PROSTATIC HYPERPLASIA MEDICATION MARKET OVERVIEW

1.1 China Benign Prostatic Hyperplasia Medication Market Sales Volume Revenue and Price 2012-2017
1.2 Global Benign Prostatic Hyperplasia Medication Market Sales Volume Revenue and Price 2012-2017
1.3 Global and China Benign Prostatic Hyperplasia Medication, by 5α-reductase inhibitors 2012-2017
  1.3.1 China Benign Prostatic Hyperplasia Medication Sales Market Share by 5α-reductase inhibitors 2012-2017
  1.3.2 Global Benign Prostatic Hyperplasia Medication Sales Market Share by 5α-reductase inhibitors 2012-2017
  1.3.3 China Benign Prostatic Hyperplasia Medication Revenue Market Share by 5α-reductase inhibitors 2012-2017
  1.3.4 Global Benign Prostatic Hyperplasia Medication Revenue Market Share by 5α-reductase inhibitors 2012-2017
  1.3.5 China Benign Prostatic Hyperplasia Medication Price by 5α-reductase inhibitors 2012-2017
  1.3.6 Global Benign Prostatic Hyperplasia Medication Price by 5α-reductase inhibitors 2012-2017
  1.3.7 Finasteride
  1.3.8 Dutasteride
  1.3.9 Epristeride
1.4 Global and China Benign Prostatic Hyperplasia Medication, by α-receptor antagonist 2012-2017
  1.4.1 China Benign Prostatic Hyperplasia Medication Sales Market Share by α-receptor antagonist 2012-2017
  1.4.2 Global Benign Prostatic Hyperplasia Medication Sales Market Share by α-receptor antagonist 2012-2017
  1.4.3 China Benign Prostatic Hyperplasia Medication Revenue Market Share by α-receptor antagonist 2012-2017
  1.4.4 Global Benign Prostatic Hyperplasia Medication Revenue Market Share by α-receptor antagonist 2012-2017
  1.4.5 China Benign Prostatic Hyperplasia Medication Price by α-receptor antagonist 2012-2017
  1.4.6 Global Benign Prostatic Hyperplasia Medication Price by α-receptor antagonist 2012-2017
  1.4.7 Pheoxbenzamine
  1.4.8 Doxazosin
  1.4.9 Alfuzosin
  1.4.10 Terazosin
  1.4.11 Prarizonaosin
  1.4.12 Tamsulosin
  1.4.13 Naftopidil
1.5 Global and China Benign Prostatic Hyperplasia Medication, by Plant Preparations 2012-2017
  1.5.1 China Benign Prostatic Hyperplasia Medication Sales Market Share by Plant Preparations 2012-2017
  1.5.2 Global Benign Prostatic Hyperplasia Medication Sales Market Share by Plant Preparations 2012-2017
  1.5.3 China Benign Prostatic Hyperplasia Medication Revenue Market Share by Plant Preparations 2012-2017
  1.5.4 Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Plant Preparations 2012-2017
  1.5.5 China Benign Prostatic Hyperplasia Medication Price by Plant Preparations 2012-2017
  1.5.6 Global Benign Prostatic Hyperplasia Medication Price by Plant Preparations 2012-2017
  1.5.7 Prostat
  1.5.8 Cernilton
  1.5.9 Compound blue palm fruit
1.6 Global and China Benign Prostatic Hyperplasia Medication, by Others 2012-2017
  1.6.1 China Benign Prostatic Hyperplasia Medication Sales Market Share by Others 2012-2017
  1.6.2 Global Benign Prostatic Hyperplasia Medication Sales Market Share by Others 2012-2017
  1.6.3 China Benign Prostatic Hyperplasia Medication Revenue Market Share by Others 2012-2017
  1.6.4 Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Others 2012-2017
  1.6.5 China Benign Prostatic Hyperplasia Medication Price by Others 2012-2017
  1.6.6 Global Benign Prostatic Hyperplasia Medication Price by Others 2012-2017
  1.6.7 Flavoxate
  1.6.8 glu-ala-glycine

CHAPTER TWO CHINA BENIGN PROSTATIC HYPERPLASIA MEDICATION MARKET BY REGIONS 2012-2017

2.1 China Benign Prostatic Hyperplasia Medication Sales Market Share by Regions 2012-2017
2.2 China Benign Prostatic Hyperplasia Medication Revenue Market Share by Regions 2012-2017
2.3 China Benign Prostatic Hyperplasia Medication Price by Regions 2012-2017
2.4 First-tier Cities
2.5 Second-tier Cities
2.6 Third-tier Cities
2.7 Other Regions

CHAPTER THREE GLOBAL BENIGN PROSTATIC HYPERPLASIA MEDICATION MARKET BY REGIONS 2012-2017

3.1 Global Benign Prostatic Hyperplasia Medication Sales Market Share by Regions 2012-2017
3.2 Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Regions 2012-2017
3.3 Global Benign Prostatic Hyperplasia Medication Price by Regions 2012-2017
3.4 Asia Pacific
  3.4.1 China
  3.4.2 Japan
  3.4.3 Korea
  3.4.4 India
  3.4.5 Others
3.5 Europe
  3.5.1 Germany
  3.5.2 United Kingdom
  3.5.3 France
  3.5.4 Italy
  3.5.5 Russia
  3.5.6 Others
3.6 North America
  3.6.1 United States
  3.6.2 Canada
3.7 Latin America
  3.7.1 Brazil
  3.7.2 Mexico
  3.7.3 Others
3.8 Southeast Asia
  3.8.1 Singapore
  3.8.2 Malaysia
  3.8.3 Vietnam
  3.8.4 Myanmar
  3.8.5 Thailand
  3.8.6 Indonesia
  3.8.7 Philippines
  3.8.8 Others
3.9 Middle East & Africa
  3.9.1 Saudi Arabia
  3.9.2 Iran
  3.9.3 UAE
  3.9.4 Turkey
  3.9.5 Israel
  3.9.6 Egypt
  3.9.7 South Africa
  3.9.8 Others

CHAPTER FOUR BENIGN PROSTATIC HYPERPLASIA MEDICATION BY PLAYERS 2012-2017

4.1 China Benign Prostatic Hyperplasia Medication Sales Volume Market Share by Players 2012-2017
4.2 China Benign Prostatic Hyperplasia Medication Revenue Share by Players 2012-2017
4.3 China Top Players Benign Prostatic Hyperplasia Medication Key Product Model and Market Performance
4.4 China Top Players Benign Prostatic Hyperplasia Medication Key Target Consumers and Market Performance

CHAPTER FIVE TOP PLAYERS PROFILE

5.1 MSD PHARMA (SINGAPORE) PTE.LTD.
  5.1.1 MSD PHARMA (SINGAPORE) PTE.LTD. Company Details and Competitors
  5.1.2 MSD PHARMA (SINGAPORE) PTE.LTD. Key Benign Prostatic Hyperplasia Medication Models and Performance
  5.1.3 MSD PHARMA (SINGAPORE) PTE.LTD. Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
  5.1.4 MSD PHARMA (SINGAPORE) PTE.LTD. Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin
5.2 Merck Sharp & Dohme Limited
  5.2.1 Merck Sharp & Dohme Limited Company Details and Competitors
  5.2.2 Merck Sharp & Dohme Limited Key Benign Prostatic Hyperplasia Medication Models and Performance
  5.2.3 Merck Sharp & Dohme Limited Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
  5.2.4 Merck Sharp & Dohme Limited Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin
5.3 GlaxoSmithKline (Ireland) Limited
  5.3.1 GlaxoSmithKline (Ireland) Limited Company Details and Competitors
  5.3.2 GlaxoSmithKline (Ireland) Limited Key Benign Prostatic Hyperplasia Medication Models and Performance
  5.3.3 GlaxoSmithKline (Ireland) Limited Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
  5.3.4 GlaxoSmithKline (Ireland) Limited Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin
5.4 Pfizer Pharma GmbH
  5.4.1 Pfizer Pharma GmbH Company Details and Competitors
  5.4.2 Pfizer Pharma GmbH Key Benign Prostatic Hyperplasia Medication Models and Performance
  5.4.3 Pfizer Pharma GmbH Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
  5.4.4 Pfizer Pharma GmbH Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin
5.5 Sanofi-Aventis France
  5.5.1 Sanofi-Aventis France Company Details and Competitors
  5.5.2 Sanofi-Aventis France Key Benign Prostatic Hyperplasia Medication Models and Performance
  5.5.3 Sanofi-Aventis France Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
  5.5.4 Sanofi-Aventis France Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin
5.6 ABBOTT LABORATORIES
  5.6.1 ABBOTT LABORATORIES Company Details and Competitors
  5.6.2 ABBOTT LABORATORIES Key Benign Prostatic Hyperplasia Medication Models and Performance
  5.6.3 ABBOTT LABORATORIES Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
  5.6.4 ABBOTT LABORATORIES Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin
5.7 Astellas Pharma Inc.
  5.7.1 Astellas Pharma Inc. Company Details and Competitors
  5.7.2 Astellas Pharma Inc. Key Benign Prostatic Hyperplasia Medication Models and Performance
  5.7.3 Astellas Pharma Inc. Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
  5.7.4 Astellas Pharma Inc. Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin
5.8 AMNEAL PHARMS
  5.8.1 AMNEAL PHARMS Company Details and Competitors
  5.8.2 AMNEAL PHARMS Key Benign Prostatic Hyperplasia Medication Models and Performance
  5.8.3 AMNEAL PHARMS Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
  5.8.4 AMNEAL PHARMS Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin
5.9 ANCHEN PHARMS
  5.9.1 ANCHEN PHARMS Company Details and Competitors
  5.9.2 ANCHEN PHARMS Key Benign Prostatic Hyperplasia Medication Models and Performance
  5.9.3 ANCHEN PHARMS Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
  5.9.4 ANCHEN PHARMS Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin
5.10 APOTEX INC
  5.10.1 APOTEX INC Company Details and Competitors
  5.10.2 APOTEX INC Key Benign Prostatic Hyperplasia Medication Models and Performance
  5.10.3 APOTEX INC Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
  5.10.4 APOTEX INC Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin
5.11 ASCENT PHARMS INC
5.12 AUROBINDO PHARMA
5.13 BARR
5.14 BIONPHARMA INC
5.15 BOEHRINGER INGELHEIM
5.16 BRECKENRIDGE PHARM
5.17 CIPLA LTD
5.18 AUROBINDO PHARMA LIMITED IN 500 038 Hyderabad
5.19 Bioindustria L.I.M. S.p.A. IT 15067 Novi Ligure
5.20 CADILA HEALTHCARE LIMITED IN 391 440 Dabhasa Village
5.21 CIPLA LIMITED IN 400 013 Mumbai
5.22 CRYSTAL PHARMA S.A.U. ES 47151 Boecillo
5.23 DR. REDDY'S LABORATORIES LIMITED IN 500 034 Hyderabad
5.24 EXCELLA GMBH & CO. KG DE 90537 Feucht
5.25 Farmak A.S. CZ 779 00 Olomouc
5.26 HETERO LABS LIMITED IN 500 018 Hyderabad
5.27 Hubei Gedian Humanwell Pharmaceutical Co., Ltd. CN 436 070 E-Zhou
5.28 MSN LABORATORIES PRIVATE LIMITED IN 502 329 Rudraram Village

CHAPTER SIX BENIGN PROSTATIC HYPERPLASIA MEDICATION BY CONSUMER 2012-2017

6.1 China Benign Prostatic Hyperplasia Medication Sales Market Share by Consumer 2012-2017
6.2 Global Benign Prostatic Hyperplasia Medication Sales Market Share by Consumer 2012-2017
6.3 urinary surgery
6.4 Pharmacy
6.5 Hospital
6.6 Clinic
6.7 Consuming Habit and Preference

CHAPTER SEVEN GLOBAL AND CHINA BENIGN PROSTATIC HYPERPLASIA MEDICATION MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)

7.1 Global and China Benign Prostatic Hyperplasia Medication Sales (), Revenue (Million USD) Forecast (2017-2022)
  7.1.1 China Benign Prostatic Hyperplasia Medication Sales (), Revenue (Million USD) Forecast (2017-2022)
  7.1.2 Global Benign Prostatic Hyperplasia Medication Sales (), Revenue (Million USD) Forecast (2017-2022)
7.2 Global and China Benign Prostatic Hyperplasia Medication Sales () Forecast by Type (2017-2022)
  7.2.1 by by 5α-reductase inhibitors
  7.2.2 by by α-receptor antagonist
  7.2.3 by Plant Preparations
  7.2.4 by Others
  7.2.5 by
7.3 Global and China Benign Prostatic Hyperplasia Medication Sales () Forecast by Application (2017-2022)
7.4 Global and China Benign Prostatic Hyperplasia Medication Sales () Forecast by Regions (2017-2022)

CHAPTER EIGHT INDUSTRY CHAIN AND SUPPLY CHAIN

8.1 Benign Prostatic Hyperplasia Medication Industry Chain Structure
  8.1.1 R&D
  8.1.2 Raw Materials (Components)
  8.1.3 Manufacturing Plants
  8.1.4 Regional Trading (Import Export and Local Sales)
  8.1.5 Online Sales Channel
  8.1.6 Offline Channel
  8.1.7 End Users
8.2 Benign Prostatic Hyperplasia Medication Manufacturing
  8.2.1 Key Components
  8.2.2 Assembly Manufacturing
8.3 Consumer Preference
8.4 Behavioral Habits
8.5 Marketing Environment

CHAPTER NINE DEVELOPMENT TREND AND RESEARCH CONCLUSION

9.1 Development Trend
9.2 Research Conclusion

CHAPTER TEN METHODOLOGY AND DATA SOURCE

10.1 Methodology/Research Approach
  10.1.1 Research Programs/Design
  10.1.2 Market Size Estimation
  10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
  10.2.1 Secondary Sources
  10.2.2 Primary Sources
10.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Table China Benign Prostatic Hyperplasia Medication Sales Volume (), Revenue (Million USD) and Price ()(2012-2017)
Figure China Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Growth Rate (2012-2017)
Figure China Benign Prostatic Hyperplasia Medication Sales Volume () and Growth Rate (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Sales Volume (), Revenue (Million USD) and Price ()(2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Growth Rate (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Sales Volume () and Growth Rate (2012-2017)
Table China Benign Prostatic Hyperplasia Medication Sales () by 5α-reductase inhibitors (2012-2017)
Table China Benign Prostatic Hyperplasia Medication Sales Market Share by 5α-reductase inhibitors (2012-2017)
Figure China Benign Prostatic Hyperplasia Medication Sales Market Share by 5α-reductase inhibitors in 2016
Table Global Benign Prostatic Hyperplasia Medication Sales () by 5α-reductase inhibitors (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Sales Market Share by 5α-reductase inhibitors (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Sales Market Share by 5α-reductase inhibitors in 2016
Table China Benign Prostatic Hyperplasia Medication Revenue (Million USD) by 5α-reductase inhibitors (2012-2017)
Table China Benign Prostatic Hyperplasia Medication Revenue Market Share by 5α-reductase inhibitors (2012-2017)
Figure China Benign Prostatic Hyperplasia Medication Revenue Market Share by 5α-reductase inhibitors in 2016
Table Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) by 5α-reductase inhibitors (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Revenue Market Share by 5α-reductase inhibitors (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Revenue Market Share by 5α-reductase inhibitors in 2016
Table China Benign Prostatic Hyperplasia Medication Price () by 5α-reductase inhibitors (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Price () by 5α-reductase inhibitors (2012-2017)
Figure China Finasteride Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure Global Finasteride Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure China Dutasteride Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure Global Dutasteride Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure China Epristeride Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure Global Epristeride Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table China Benign Prostatic Hyperplasia Medication Sales () by α-receptor antagonist (2012-2017)
Table China Benign Prostatic Hyperplasia Medication Sales Market Share by α-receptor antagonist (2012-2017)
Figure China Benign Prostatic Hyperplasia Medication Sales Market Share by α-receptor antagonist in 2016
Table Global Benign Prostatic Hyperplasia Medication Sales () by α-receptor antagonist (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Sales Market Share by α-receptor antagonist (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Sales Market Share by α-receptor antagonist in 2016
Table China Benign Prostatic Hyperplasia Medication Revenue (Million USD) by α-receptor antagonist (2012-2017)
Table China Benign Prostatic Hyperplasia Medication Revenue Market Share by α-receptor antagonist (2012-2017)
Figure China Benign Prostatic Hyperplasia Medication Revenue Market Share by α-receptor antagonist in 2016
Table Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) by α-receptor antagonist (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Revenue Market Share by α-receptor antagonist (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Revenue Market Share by α-receptor antagonist in 2016
Table China Benign Prostatic Hyperplasia Medication Price () by α-receptor antagonist (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Price () by α-receptor antagonist (2012-2017)
Figure China Pheoxbenzamine Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure Global Pheoxbenzamine Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure China Doxazosin Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure Global Doxazosin Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure China Alfuzosin Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure Global Alfuzosin Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure China Terazosin Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure Global Terazosin Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure China Prarizonaosin Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure Global Prarizonaosin Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table China Benign Prostatic Hyperplasia Medication Sales () by Plant Preparations (2012-2017)
Table China Benign Prostatic Hyperplasia Medication Sales Market Share by Plant Preparations (2012-2017)
Figure China Benign Prostatic Hyperplasia Medication Sales Market Share by Plant Preparations in 2016
Table Global Benign Prostatic Hyperplasia Medication Sales () by Plant Preparations (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Sales Market Share by Plant Preparations (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Sales Market Share by Plant Preparations in 2016
Table China Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Plant Preparations (2012-2017)
Table China Benign Prostatic Hyperplasia Medication Revenue Market Share by Plant Preparations (2012-2017)
Figure China Benign Prostatic Hyperplasia Medication Revenue Market Share by Plant Preparations in 2016
Table Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Plant Preparations (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Plant Preparations (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Plant Preparations in 2016
Table China Benign Prostatic Hyperplasia Medication Price () by Plant Preparations (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Price () by Plant Preparations (2012-2017)
Figure China Prostat Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure Global Prostat Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure China Cernilton Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure Global Cernilton Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure China Compound blue palm fruit Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure Global Compound blue palm fruit Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table China Benign Prostatic Hyperplasia Medication Sales () by Others (2012-2017)
Table China Benign Prostatic Hyperplasia Medication Sales Market Share by Others (2012-2017)
Figure China Benign Prostatic Hyperplasia Medication Sales Market Share by Others in 2016
Table Global Benign Prostatic Hyperplasia Medication Sales () by Others (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Sales Market Share by Others (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Sales Market Share by Others in 2016
Table China Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Others (2012-2017)
Table China Benign Prostatic Hyperplasia Medication Revenue Market Share by Others (2012-2017)
Figure China Benign Prostatic Hyperplasia Medication Revenue Market Share by Others in 2016
Table Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Others (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Others (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Others in 2016
Table China Benign Prostatic Hyperplasia Medication Price () by Others (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Price () by Others (2012-2017)
Figure China Flavoxate Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure Global Flavoxate Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure China glu-ala-glycine Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure Global glu-ala-glycine Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table China Benign Prostatic Hyperplasia Medication Sales () by (2012-2017)
Table China Benign Prostatic Hyperplasia Medication Sales Market Share by (2012-2017)
Figure China Benign Prostatic Hyperplasia Medication Sales Market Share by in 2016
Table Global Benign Prostatic Hyperplasia Medication Sales () by (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Sales Market Share by (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Sales Market Share by in 2016
Table China Benign Prostatic Hyperplasia Medication Revenue (Million USD) by (2012-2017)
Table China Benign Prostatic Hyperplasia Medication Revenue Market Share by (2012-2017)
Figure China Benign Prostatic Hyperplasia Medication Revenue Market Share by in 2016
Table Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) by (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Revenue Market Share by (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Revenue Market Share by in 2016
Table China Benign Prostatic Hyperplasia Medication Price () by (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Price () by (2012-2017)
Table China Benign Prostatic Hyperplasia Medication Sales () by Regions (2012-2017)
Table China Benign Prostatic Hyperplasia Medication Sales Share by Regions (2012-2017)
Figure China Benign Prostatic Hyperplasia Medication Sales Market Share by Regions in 2016
Figure China Benign Prostatic Hyperplasia Medication Sales Market Share by Regions in 2017
Table China Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share by Regions (2012-2017)
Table China Benign Prostatic Hyperplasia Medication Revenue Market Share by Regions (2012-2017)
Figure China Benign Prostatic Hyperplasia Medication Revenue Market Share by Regions in 2016
Figure China Benign Prostatic Hyperplasia Medication Revenue Market Share by Regions in 2017
Table China Benign Prostatic Hyperplasia Medication Price () by Regions (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Sales () by Regions (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Sales Share by Regions (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Sales Market Share by Regions in 2016
Figure Global Benign Prostatic Hyperplasia Medication Sales Market Share by Regions in 2017
Table Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share by Regions (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Regions (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Regions in 2016
Figure Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Regions in 2017
Table Global Benign Prostatic Hyperplasia Medication Price () by Regions (2012-2017)
Table Asia Pacific Benign Prostatic Hyperplasia Medication Sales () by Regions (2012-2017)
Table Asia Pacific Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Regions (2012-2017)
Table Top Companies of Asia Pacific Benign Prostatic Hyperplasia Medication Business Strategy, Channel and Performance List
Figure Asia Pacific Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Europe Benign Prostatic Hyperplasia Medication Sales () by Regions (2012-2017)
Table Europe Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Regions (2012-2017)
Table Top Companies of Europe Benign Prostatic Hyperplasia Medication Business Strategy, Channel and Performance List
Figure Europe Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table North America Benign Prostatic Hyperplasia Medication Sales () by Regions (2012-2017)
Table North America Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Regions (2012-2017)
Table Top Companies of North America Benign Prostatic Hyperplasia Medication Business Strategy, Channel and Performance List
Figure North America Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Latin America Benign Prostatic Hyperplasia Medication Sales () by Regions (2012-2017)
Table Latin America Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Regions (2012-2017)
Table Top Companies of Latin America Benign Prostatic Hyperplasia Medication Business Strategy, Channel and Performance List
Figure Latin America Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Southeast Asia Benign Prostatic Hyperplasia Medication Sales () by Regions (2012-2017)
Table Southeast Asia Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Regions (2012-2017)
Table Top Companies of Southeast Asia Benign Prostatic Hyperplasia Medication Business Strategy, Channel and Performance List
Figure Southeast Asia Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Middle East & Africa Benign Prostatic Hyperplasia Medication Sales () by Regions (2012-2017)
Table Middle East & Africa Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Regions (2012-2017)
Table Top Companies of Middle East & Africa Benign Prostatic Hyperplasia Medication Business Strategy, Channel and Performance List
Figure Middle East & Africa Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure South Africa Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table China Benign Prostatic Hyperplasia Medication Sales Volume () by Key Players (2012-2017)
Table China Benign Prostatic Hyperplasia Medication Sales Volume Market Share by Key Players (2012-2017)
Figure China Benign Prostatic Hyperplasia Medication Sales Volume Market Share by Key Players 2016
Figure China Benign Prostatic Hyperplasia Medication Sales Volume Market Share by Key Players 2017
Table China Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Key Players (2012-2017)
Table China Benign Prostatic Hyperplasia Medication Revenue Market Share by Key Players (2012-2017)
Figure China Benign Prostatic Hyperplasia Medication Revenue Market Share by Key Players 2016
Figure China Benign Prostatic Hyperplasia Medication Revenue Market Share by Key Players 2017
Table China Top Brands Key Product Model and Market Performance
Table China Top Brands Key Target Consumers and Market Performance
Table MSD PHARMA (SINGAPORE) PTE.LTD. Company Details and Competitors
Table MSD PHARMA (SINGAPORE) PTE.LTD. Key Benign Prostatic Hyperplasia Medication Models and Performance
Table MSD PHARMA (SINGAPORE) PTE.LTD. Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
Table MSD PHARMA (SINGAPORE) PTE.LTD. Benign Prostatic Hyperplasia Medication Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure MSD PHARMA (SINGAPORE) PTE.LTD. Benign Prostatic Hyperplasia Medication Sales() and Growth Rate (%)(2012-2017)
Figure MSD PHARMA (SINGAPORE) PTE.LTD. Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Global (2012-2017)
Figure MSD PHARMA (SINGAPORE) PTE.LTD. Benign Prostatic Hyperplasia Medication Sales Revenue(Million USD) and Growth Rate (%)(2012-2017)
Figure MSD PHARMA (SINGAPORE) PTE.LTD. Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Global (2012-2017)
Table Merck Sharp & Dohme Limited Company Details and Competitors
Table Merck Sharp & Dohme Limited Key Benign Prostatic Hyperplasia Medication Models and Performance
Table Merck Sharp & Dohme Limited Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
Table Merck Sharp & Dohme Limited Benign Prostatic Hyperplasia Medication Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure Merck Sharp & Dohme Limited Benign Prostatic Hyperplasia Medication Sales() and Growth Rate (%)(2012-2017)
Figure Merck Sharp & Dohme Limited Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Global (2012-2017)
Figure Merck Sharp & Dohme Limited Benign Prostatic Hyperplasia Medication Sales Revenue(Million USD) and Growth Rate (%)(2012-2017)
Figure Merck Sharp & Dohme Limited Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Global (2012-2017)
Table GlaxoSmithKline (Ireland) Limited Company Details and Competitors
Table GlaxoSmithKline (Ireland) Limited Key Benign Prostatic Hyperplasia Medication Models and Performance
Table GlaxoSmithKline (Ireland) Limited Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
Table GlaxoSmithKline (Ireland) Limited Benign Prostatic Hyperplasia Medication Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure GlaxoSmithKline (Ireland) Limited Benign Prostatic Hyperplasia Medication Sales() and Growth Rate (%)(2012-2017)
Figure GlaxoSmithKline (Ireland) Limited Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Global (2012-2017)
Figure GlaxoSmithKline (Ireland) Limited Benign Prostatic Hyperplasia Medication Sales Revenue(Million USD) and Growth Rate (%)(2012-2017)
Figure GlaxoSmithKline (Ireland) Limited Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Global (2012-2017)
Table Pfizer Pharma GmbH Company Details and Competitors
Table Pfizer Pharma GmbH Key Benign Prostatic Hyperplasia Medication Models and Performance
Table Pfizer Pharma GmbH Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
Table Pfizer Pharma GmbH Benign Prostatic Hyperplasia Medication Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure Pfizer Pharma GmbH Benign Prostatic Hyperplasia Medication Sales() and Growth Rate (%)(2012-2017)
Figure Pfizer Pharma GmbH Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Global (2012-2017)
Figure Pfizer Pharma GmbH Benign Prostatic Hyperplasia Medication Sales Revenue(Million USD) and Growth Rate (%)(2012-2017)
Figure Pfizer Pharma GmbH Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Global (2012-2017)
Table Sanofi-Aventis France Company Details and Competitors
Table Sanofi-Aventis France Key Benign Prostatic Hyperplasia Medication Models and Performance
Table Sanofi-Aventis France Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
Table Sanofi-Aventis France Benign Prostatic Hyperplasia Medication Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure Sanofi-Aventis France Benign Prostatic Hyperplasia Medication Sales() and Growth Rate (%)(2012-2017)
Figure Sanofi-Aventis France Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Global (2012-2017)
Figure Sanofi-Aventis France Benign Prostatic Hyperplasia Medication Sales Revenue(Million USD) and Growth Rate (%)(2012-2017)
Figure Sanofi-Aventis France Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Global (2012-2017)
Table ABBOTT LABORATORIES Company Details and Competitors
Table ABBOTT LABORATORIES Key Benign Prostatic Hyperplasia Medication Models and Performance
Table ABBOTT LABORATORIES Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
Table ABBOTT LABORATORIES Benign Prostatic Hyperplasia Medication Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure ABBOTT LABORATORIES Benign Prostatic Hyperplasia Medication Sales() and Growth Rate (%)(2012-2017)
Figure ABBOTT LABORATORIES Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Global (2012-2017)
Figure ABBOTT LABORATORIES Benign Prostatic Hyperplasia Medication Sales Revenue(Million USD) and Growth Rate (%)(2012-2017)
Figure ABBOTT LABORATORIES Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Global (2012-2017)
Table Astellas Pharma Inc. Company Details and Competitors
Table Astellas Pharma Inc. Key Benign Prostatic Hyperplasia Medication Models and Performance
Table Astellas Pharma Inc. Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
Table Astellas Pharma Inc. Benign Prostatic Hyperplasia Medication Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure Astellas Pharma Inc. Benign Prostatic Hyperplasia Medication Sales() and Growth Rate (%)(2012-2017)
Figure Astellas Pharma Inc. Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Global (2012-2017)
Figure Astellas Pharma Inc. Benign Prostatic Hyperplasia Medication Sales Revenue(Million USD) and Growth Rate (%)(2012-2017)
Figure Astellas Pharma Inc. Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Global (2012-2017)
Table AMNEAL PHARMS Company Details and Competitors
Table AMNEAL PHARMS Key Benign Prostatic Hyperplasia Medication Models and Performance
Table AMNEAL PHARMS Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
Table AMNEAL PHARMS Benign Prostatic Hyperplasia Medication Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure AMNEAL PHARMS Benign Prostatic Hyperplasia Medication Sales() and Growth Rate (%)(2012-2017)
Figure AMNEAL PHARMS Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Global (2012-2017)
Figure AMNEAL PHARMS Benign Prostatic Hyperplasia Medication Sales Revenue(Million USD) and Growth Rate (%)(2012-2017)
Figure AMNEAL PHARMS Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Global (2012-2017)
Table ANCHEN PHARMS Company Details and Competitors
Table ANCHEN PHARMS Key Benign Prostatic Hyperplasia Medication Models and Performance
Table ANCHEN PHARMS Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
Table ANCHEN PHARMS Benign Prostatic Hyperplasia Medication Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure ANCHEN PHARMS Benign Prostatic Hyperplasia Medication Sales() and Growth Rate (%)(2012-2017)
Figure ANCHEN PHARMS Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Global (2012-2017)
Figure ANCHEN PHARMS Benign Prostatic Hyperplasia Medication Sales Revenue(Million USD) and Growth Rate (%)(2012-2017)
Figure ANCHEN PHARMS Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Global (2012-2017)
Table APOTEX INC Company Details and Competitors
Table APOTEX INC Key Benign Prostatic Hyperplasia Medication Models and Performance
Table APOTEX INC Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
Table APOTEX INC Benign Prostatic Hyperplasia Medication Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure APOTEX INC Benign Prostatic Hyperplasia Medication Sales() and Growth Rate (%)(2012-2017)
Figure APOTEX INC Benign Prostatic Hyperplasia Medication Sales Market Share (%) in Global (2012-2017)
Figure APOTEX INC Benign Prostatic Hyperplasia Medication Sales Revenue(Million USD) and Growth Rate (%)(2012-2017)
Figure APOTEX INC Benign Prostatic Hyperplasia Medication Revenue Market Share (%) in Global (2012-2017)
Table ASCENT PHARMS INC Company Details and Competitors
Table AUROBINDO PHARMA Company Details and Competitors
Table BARR Company Details and Competitors
Table BIONPHARMA INC Company Details and Competitors
Table BOEHRINGER INGELHEIM Company Details and Competitors
Table BRECKENRIDGE PHARM Company Details and Competitors
Table CIPLA LTD Company Details and Competitors
Table AUROBINDO PHARMA LIMITED IN 500 038 Hyderabad Company Details and Competitors
Table Bioindustria L.I.M. S.p.A. IT 15067 Novi Ligure Company Details and Competitors
Table CADILA HEALTHCARE LIMITED IN 391 440 Dabhasa Village Company Details and Competitors
Table CIPLA LIMITED IN 400 013 Mumbai Company Details and Competitors
Table CRYSTAL PHARMA S.A.U. ES 47151 Boecillo Company Details and Competitors
Table DR. REDDY'S LABORATORIES LIMITED IN 500 034 Hyderabad Company Details and Competitors
Table EXCELLA GMBH & CO. KG DE 90537 Feucht Company Details and Competitors
Table Farmak A.S. CZ 779 00 Olomouc Company Details and Competitors
Table HETERO LABS LIMITED IN 500 018 Hyderabad Company Details and Competitors
Table Hubei Gedian Humanwell Pharmaceutical Co., Ltd. CN 436 070 E-Zhou Company Details and Competitors
Table MSN LABORATORIES PRIVATE LIMITED IN 502 329 Rudraram Village Company Details and Competitors
Table China Benign Prostatic Hyperplasia Medication Sales () by Consumer (2012-2017)
Figure China Benign Prostatic Hyperplasia Medication Sales Market Share by Consumer (2012-2017)
Figure China Benign Prostatic Hyperplasia Medication Sales Market Share by Consumer in 2016
Table Global Benign Prostatic Hyperplasia Medication Sales () by Consumer (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Sales Market Share by Consumer (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Sales Market Share by Consumer in 2016
Figure China urinary surgery Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure Global urinary surgery Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure China Pharmacy Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure Global Pharmacy Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure China Hospital Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure Global Hospital Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure China Clinic Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure Global Clinic Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure China Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (%) Forecast (2017-2022)
Figure China Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure China Benign Prostatic Hyperplasia Medication Price () Trend Forecast (2017-2022)
Figure Global Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (%) Forecast (2017-2022)
Figure Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure Global Benign Prostatic Hyperplasia Medication Price () Trend Forecast (2017-2022)
Table China Benign Prostatic Hyperplasia Medication Sales () Forecast by Type (2017-2022)
Table Global Benign Prostatic Hyperplasia Medication Sales () Forecast by Type (2017-2022)
Figure China Benign Prostatic Hyperplasia Medication Sales () Forecast by Type (2017-2022)
Figure Global Benign Prostatic Hyperplasia Medication Sales () Forecast by Type (2017-2022)
Figure China Benign Prostatic Hyperplasia Medication Sales Volume Market Share Forecast by Type in 2017
Figure Global Benign Prostatic Hyperplasia Medication Sales Volume Market Share Forecast by Type in 2017
Table China Benign Prostatic Hyperplasia Medication Sales () Forecast by Application (2017-2022)
Table Global Benign Prostatic Hyperplasia Medication Sales () Forecast by Application (2017-2022)
Figure China Benign Prostatic Hyperplasia Medication Sales Volume Market Share Forecast by Application (2017-2022)
Figure Global Benign Prostatic Hyperplasia Medication Sales Volume Market Share Forecast by Application (2017-2022)
Figure China Benign Prostatic Hyperplasia Medication Sales Volume Market Share Forecast by Application in 2017
Figure Global Benign Prostatic Hyperplasia Medication Sales Volume Market Share Forecast by Application in 2017
Table China Benign Prostatic Hyperplasia Medication Sales () Forecast by Regions (2017-2022)
Table Global Benign Prostatic Hyperplasia Medication Sales Volume Share Forecast by Regions (2017-2022)
Table China Benign Prostatic Hyperplasia Medication Sales Volume Share Forecast by Regions (2017-2022)
Table Global Benign Prostatic Hyperplasia Medication Sales () Forecast by Regions (2017-2022)
Figure China Benign Prostatic Hyperplasia Medication Sales Volume Share Forecast by Regions (2017-2022)
Figure Global Benign Prostatic Hyperplasia Medication Sales Volume Share Forecast by Regions (2017-2022)